| Drug ID: | Drug159 |
|---|---|
| Drug Name: | Ritlecitinib |
| CID: | 118115473 |
| DrugBank ID: | DB14924 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT02958865 |
| Molecular Formula: | C15H19N5O |
| Molecular Weight: | 285.34 g/mol |
| Isomeric SMILES: | C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3 |
| Synonyms: | ritlecitinib; PF-06651600; 2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-; 2OYE00PC25; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one; PF06651600; RITLECITINIB [INN]; UNII-2OYE00PC25; RITLECITINIB [WHO-DD]; PF 06651600 |
| Phase 0: | 0 |
| Phase 1: | 31 |
| Phase 2: | 21 |
| Phase 3: | 12 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1210 | 118115473 | Ritlecitinib | 695 | BTK | Homo sapiens (human) | Inhibitor | |
| dt1211 | 118115473 | Ritlecitinib | 7294 | TXK | Homo sapiens (human) | Inhibitor | |
| dt1212 | 118115473 | Ritlecitinib | 3718 | JAK3 | Homo sapiens (human) | None | |
| dt1213 | 118115473 | Ritlecitinib | 3718 | JAK3 | Homo sapiens (human) | 31082193 | Tyrosine-protein kinase JAK3 inhibitor |
| dt1214 | 118115473 | Ritlecitinib | 3718 | JAK3 | Homo sapiens (human) | Inhibition | |
| dt1215 | 118115473 | Ritlecitinib | 3716 | JAK1 | Homo sapiens (human) | 28139931 | Inhibition |
| dt1216 | 118115473 | Ritlecitinib | 3718 | JAK3 | Homo sapiens (human) | 27791347 | None |
| dt1217 | 118115473 | Ritlecitinib | 660 | BMX | Homo sapiens (human) | 27791347 | None |
| dt1218 | 118115473 | Ritlecitinib | 3702 | ITK | Homo sapiens (human) | 27791347 | None |
| dt1219 | 118115473 | Ritlecitinib | 7294 | TXK | Homo sapiens (human) | 27791347 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02958865 | Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Dru…
PMID: 37917289
Year: 2023
Relationship Type:
Clinical Trial
Score: 7.5
BACKGROUND: Ritlecitinib is an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family inhibitor undergoing parallel clinica…
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: R…
PMID: 36623678
Year: 2023
Relationship Type:
Treatment
Score: 7.5
BACKGROUND & AIMS: The efficacy and safety of ritlecitinib (oral JAK3/TEC family kinase inhibitor) and brepocitinib (oral TYK2/JAK1 inhibitor) as ind…
The Stability-Indicating Ultra High-Performance Liquid Chromatography with Diod…
PMID: 39861185
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND/OBJECTIVES: Janus kinase inhibitors open new horizons for small-molecule drugs in treating inflammatory bowel disease, with ritlecitinib d…
Ritlecitinib: First Approval
PMID: 37556041
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Ritlecitinib (LITFULO()), an orally administered kinase inhibitor, is being developed by Pfizer for the treatment of alopecia areata, vitiligo, ulcer…